Palisade Bio reaction to PALI-2108 data ‘looks misaligned’, says Clear Street

Clear Street keeps a Buy rating and $12 price target on Palisade Bio (PALI), saying the decline in the stock price after the Phase 1B Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease looks misaligned with fundamentals. Together with previously disclosed UC data, the findings provide compelling validation and a strong foundation for PALI-2108’s success, and the stock price decline is more timing-driven than data-driven, the analyst tells investors in a research note.